Xagena Medicina

The FDA ( Food and Drug Administration ) has completed a safety review of Multaq ( Dronedarone ). This review showed that Multaq increased the risk of serious cardiovascular events, including death, w ...

The Committee for Medicinal Products for Human Use ( CHMP ) has adopted a positive opinion recommending a change to the terms of the marketing authorisation for the medicinal product Pradaxa ( Dabigat ...

Gilead Sciences has announced results from HARMONY, a randomized, double-blind, placebo-controlled phase 2 study evaluating the effect of Ranolazine and low-dose Dronedarone, each given alone and in c ...

Before initiating antiarrhythmic drug therapy, treatment of precipitating or reversible causes of atrial fibrillation is recommended. ( Class I; Level of Evidence: C ) The following antiarrhythmic ...

Management of patients with complications of Parkinson's disease remains a challenge for both the clinician and the patient. These complications may be a result of the natural course of the disease ...

Two studies strongly suggest that a mutation in a recently discovered gene is the most common genetic cause of Parkinson’s disease identified to date. The findings could lead to the development of ...

A study evaluated the effect of vitamin C, vitamin E, and beta-carotene intake on the risk of Parkinson's disease ( PD ). Researchers did a systematic review and meta-analysis of observational stud ...

A study examinated failures from deep brain stimulation ( DBS ) surgery for movement disorders. Since the Food and Drug Administration ( FDA ) approved deep brain stimulation for the treatment of P ...